Today’s Research Reports on Trending Tickers: Clovis Oncology Inc. and Intercept Pharmaceuticals Inc.
U.S. markets were dragged down by shares of Amazon.com Friday after the online retailer posted earnings that fell short of expectations. The S&P 500 Index fell 0.13 percent to close at 2,472.10, down 0.02 percent for the week, while the Nasdaq Composite index declined 0.12 percent to close at 6,374.68, down 0.2 percent for the week. The Dow Jones Industrial Average managed to hit new intraday and closing highs Thursday as the Index was lifted by strong earnings from Chevron. The Dow gained 0.15 percent to close at 21,830.31, up 1.16 percent for the week. Additionally, the Commerce Department reported gross domestic product (GDP) rose at an annual rate of 2.6% in the second quarter, compared to just a 1.2 percent pace in the first quarter of 2017.
“It is not surprising for market participants to take profits after a big rally, especially going into August, which is historically a difficult month,” said Quincy Krosby, chief market strategist at Prudential Financial.
RDI Initiates Coverage on:
Clovis Oncology Inc.
Intercept Pharmaceuticals Inc.
Clovis Oncology Inc.’s stock moved 6.25% higher Friday, to close the day at $98.02. The stock recorded a trading volume of 2,366,057 shares, which was above its three months average volume of 1,943,700 shares. In the last year, Clovis Oncology Inc.’s shares have traded in a range of 13.71 – 99.45. The share price has gained 614.95% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. Moreover, the stock’s 50-day moving average of $86.19 is greater than its 200-day moving average of $65.59. Shares of Clovis Oncology Inc. have gained approximately 120.67 percent year-to-date.
Access RDI’s Clovis Oncology Inc. Research Report at:
On Friday, shares in Intercept Pharmaceuticals Inc. recorded a trading volume of 755,345 shares, which was above the three months average volume of 365,803 shares. The stock ended the day 4.22% higher at 135.03. The share price has gained 39.74% from its 52 week low with a 52 week trading range of 96.63 – 177.93.The company’s shares are currently trading above their 200-day moving average. Moreover, the stock’s 50-day moving average of $125.13 is greater than its 200-day moving average of $118.08. Shares of Intercept Pharmaceuticals Inc. have gained approximately 24.28 percent year-to-date.
Access RDI’s Intercept Pharmaceuticals Inc. Research Report at:
Our Actionable Research on Clovis Oncology, Inc. (NASDAQ:CLVS) and Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.